World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
35594
World Ranking
13467
National Ranking
6847

Susan Halabi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Susan Halabi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 458 publications — 50th percentile

50% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Susan Halabi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Susan Halabi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2015 - Fellow of the American Statistical Association (ASA)

Overview

Susan Halabi is affiliated with Duke University in the United States and has a research focus primarily within the field of Medicine. Their work spans several subfields including Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Statistics and Probability, and Radiology, Nuclear Medicine and Imaging.

The scientist's research concentrates on multiple main topics such as:

  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Cancer, Lipids, and Metabolism
  • Radiopharmaceutical Chemistry and Applications
  • Cancer Immunotherapy and Biomarkers
  • Statistical Methods in Clinical Trials

Susan Halabi has contributed to a number of scientific papers published in well-known academic journals. Some recent publications include:

  • The Lancet Commission on prostate cancer: planning for the surge in cases, 2024, published in The Lancet
  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019, 2020, published in European Urology
  • Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium, 2021, published in Annals of Oncology
  • Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19, 2021, published in JAMA Oncology
  • Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study, 2021, published in Journal of Clinical Oncology

Their frequent co-authors include:

  • Andrew J. Armstrong
  • Elizabeth Garrett-Mayer
  • Richard L. Schilsky
  • Pam K. Mangat
  • Michael J. Morris

Common publication venues where Susan Halabi's work appears are:

  • Journal of Clinical Oncology
  • JCO Precision Oncology
  • Annals of Oncology
  • European Urology
  • UNC Libraries

Award recognition includes being named a Fellow of the American Statistical Association (ASA) in 2015.

Best Publications

  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

    Howard I. Scher;Susan Halabi;Ian Tannock;Michael Morris

  • A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.

    Robert S. Sandler;Susan Halabi;John A. Baron;Susan Budinger

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

    Glenn J. Bubley;Michael Carducci;William Dahut;Nancy Dawson

  • Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study

    Philip W. Kantoff;Susan Halabi;Mark Conaway;Joel Picus

  • Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

    Brian I Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler

  • Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

    Brian I. Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler

  • Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer

    Susan Halabi;Eric J. Small;Philip W. Kantoff;Michael W. Kattan

  • Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

    Toni K. Choueiri;Susan Halabi;Ben L. Sanford;Olwen Hahn

  • Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

    Eric J. Small;Susan Halabi;Nancy A. Dawson;Walter M. Stadler

  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran

  • Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials

    Bernard F. Cole;Richard F. Logan;Susan Halabi;Robert Benamouzig

  • American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma

    Robert A. Kyle;Gary C. Yee;Mark R. Somerfield;Patrick J. Flynn

  • Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663

    Mary-Ellen Taplin;Barur Rajeshkumar;Susan Halabi;Cary P. Werner

  • Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

    Susan Halabi;Chen-Yen Lin;W. Kevin Kelly;Karim S. Fizazi

  • Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780

    D. M. Savarese;S. Halabi;V. Hars;W. L. Akerley

  • Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

    Andrew J Armstrong;Susan Halabi;Tim Eisen;Samuel Broderick

  • Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

    William Kevin Kelly;Susan Halabi;Michael Carducci;Daniel George

  • Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

    Susan Halabi;William Kevin Kelly;Hua Ma;Haojin Zhou

  • A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

    Robert S. Sandler;Susan Halabi;John A. Baron;Susan Budinger

Frequent Co-Authors

Eric J. Small
Eric J. Small University of California, San Francisco
Daniel J. George
Daniel J. George Duke University
Andrew J. Armstrong
Andrew J. Armstrong Duke University
Michael J. Morris
Michael J. Morris Memorial Sloan Kettering Cancer Center
Philip W. Kantoff
Philip W. Kantoff Memorial Sloan Kettering Cancer Center
Walter M. Stadler
Walter M. Stadler University of Chicago
Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
Mary-Ellen Taplin
Mary-Ellen Taplin Harvard University
Oliver Sartor
Oliver Sartor Tulane University
Richard L. Schilsky
Richard L. Schilsky University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring career paths related to Medicine in the USA often means considering flexible, high-demand healthcare degrees. RN to BSN programs are a popular option for registered nurses seeking to advance their education and unlock broader career opportunities—all with minimal or no in-person clinical requirements.

For those interested in healthcare leadership, finding which online healthcare administration programs have cahme accreditation? is crucial. Accreditation from CAHME ensures program quality and boosts employability for roles in hospital administration and management.

Advanced practice nurses or those seeking executive roles can benefit from online dnp programs. These doctorates often offer flexible, accelerated pathways ideal for working professionals. Additionally, students preferring a more streamlined academic experience may explore dnp programs without dissertation, which can provide a quicker route to the highest clinical nursing qualifications.

Each of these pathways offers unique benefits and can help you tailor your educational journey in healthcare, whether your goal is patient care, leadership, or specialized clinical practice.

Best Scientists Citing Susan Halabi

Trending Scientists

Recently Published Articles